Loading clinical trials...
Loading clinical trials...
Biopsies are performed in several autoimmune diseases to diagnose or classify them Tolerance and information of the patients have been poorly evlauated our objective is to evaluate tolerance and information of the patients after the biopsies for salivary gland, temporal arteries and neuromuscular.
patinets that benefited of arterial temporal biospy or salivary gland biospy or muscuar biopsy or neuro muscular biospy for his auto -mmune disease will be included and fill standardized questionnaires concerning tolerance, information and side effect at inclusion , day 7 and day 30 after the biopsy data will be analysed to evaluate information, tolerance and risk factor af side effect
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
CHU d'ANGERS
Angers, France
CHU de Bordeaux
Bordeaux, France
CHRU de Brest
Brest, France
CHU de LILLE
Lille, France
CHU de Marseille
Marseille, France
Hôpital de la Salpétrière
Paris, France
CH de Quimper
Quimper, France
CHU de Tours
Tours, France
Start Date
August 19, 2021
Primary Completion Date
February 18, 2025
Completion Date
February 18, 2025
Last Updated
April 5, 2024
600
ESTIMATED participants
Lead Sponsor
University Hospital, Brest
NCT07422272
NCT06603883
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05441982